These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 33314759)
21. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501 [TBL] [Abstract][Full Text] [Related]
22. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q Front Oncol; 2021; 11():751106. PubMed ID: 35273907 [TBL] [Abstract][Full Text] [Related]
24. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
25. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959 [TBL] [Abstract][Full Text] [Related]
26. Molecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling panel. Kage H; Kohsaka S; Tatsuno K; Watanabe K; Shinozaki-Ushiku A; Isago H; Ushiku T; Aburatani H; Mano H; Oda K Respir Investig; 2024 Sep; 62(5):910-913. PubMed ID: 39126824 [TBL] [Abstract][Full Text] [Related]
27. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. Araujo LH; Lammers PE; Matthews-Smith V; Eisenberg R; Gonzalez A; Schwartz AG; Timmers C; Shilo K; Zhao W; Natarajan TG; Zhang J; Yilmaz AS; Liu T; Coombes K; Carbone DP J Thorac Oncol; 2015 Oct; 10(10):1430-6. PubMed ID: 26301800 [TBL] [Abstract][Full Text] [Related]
28. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591 [TBL] [Abstract][Full Text] [Related]
29. Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. Si X; Pan R; Ma S; Li L; Liang L; Zhang P; Chu Y; Wang H; Wang M; Zhang X; Zhang L Thorac Cancer; 2021 Feb; 12(3):357-363. PubMed ID: 33300283 [TBL] [Abstract][Full Text] [Related]
30. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Ma C; Yang X; Xing W; Yu H; Si T; Guo Z Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608 [TBL] [Abstract][Full Text] [Related]
31. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428 [TBL] [Abstract][Full Text] [Related]
32. Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. Couto PP; Bastos-Rodrigues L; Schayek H; Melo FM; Lisboa RGC; Miranda DM; Vilhena A; Bale AE; Friedman E; De Marco L Carcinogenesis; 2017 Oct; 38(11):1112-1118. PubMed ID: 28968711 [TBL] [Abstract][Full Text] [Related]
33. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302 [TBL] [Abstract][Full Text] [Related]
34. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084 [TBL] [Abstract][Full Text] [Related]
35. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]
36. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Liang WS; Vergilio JA; Salhia B; Huang HJ; Oki Y; Garrido-Laguna I; Park H; Westin JR; Meric-Bernstam F; Fabrizio D; Miller VA; Stephens PJ; Fanale MA; Ross JS; Janku F Oncologist; 2019 Feb; 24(2):219-228. PubMed ID: 30108156 [TBL] [Abstract][Full Text] [Related]
38. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G; Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916 [TBL] [Abstract][Full Text] [Related]
39. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden. van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052 [TBL] [Abstract][Full Text] [Related]
40. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer. Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]